Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | RARA | P10276 | 3/20 | 0.40 |
| ▸ | RARB | P10826 | 3/20 | 0.40 |
| ▸ | RARG | P13631 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152509 | 0.90 | PTGS1 (0.45) | PTGS1CHEK2PARP1ARMAOB | |
| SCHEMBL20021930 | 0.89 | MPL (0.47) | PTGS1CHEK2RARBAR | |
| SCHEMBL18152554 | 0.83 | PTGS1 (0.40) | PTGS1CHEK2PARP1ARMAOB | |
| SCHEMBL18152339 | 0.82 | PTGS1 (0.48) | PTGS1CHEK2PARP1ARMAOB | |
| Hydrochloric Acid SCHEMBL18152459 | 0.82 | PTGS1 (0.48) | PTGS1CHEK2PARP1ARMAOB | |
| Hydrochloric Acid SCHEMBL30460805 | 0.79 | CA2 (0.55) | CHEK2CA2PARP1MAOBPARP10 | |
| SCHEMBL18152492 | 0.79 | GRM2 (0.39) | PTGS1ARACLYGRM2MKNK2 | |
| SCHEMBL18152491 | 0.78 | HTR2A (0.37) | PTGS1CHEK2CA2MAP4K4MKNK2 | |
| SCHEMBL18165202 | 0.77 | PSMD10 (0.41) | PTGS1GRM2 | |
| SCHEMBL18152340 | 0.76 | PTGS1 (0.42) | PTGS1CHEK2PARP1ARMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | PTGS1 4219/4885CHEK2 3638/4885CA2 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.